Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Rocha Lima CM, et al. Among authors: miller ll, miller w. J Clin Oncol. 2002 Mar 1;20(5):1182-91. doi: 10.1200/JCO.2002.20.5.1182. J Clin Oncol. 2002. PMID: 11870159 Clinical Trial.
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. Among authors: miller ll. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Drengler RL, et al. Among authors: miller ll. J Clin Oncol. 1999 Feb;17(2):685-96. doi: 10.1200/JCO.1999.17.2.685. J Clin Oncol. 1999. PMID: 10080615 Clinical Trial.
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD. Rothenberg ML, et al. Among authors: miller ll. Ann Oncol. 2001 Nov;12(11):1631-41. doi: 10.1023/a:1013157727506. Ann Oncol. 2001. PMID: 11822765 Free article. Clinical Trial.
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Schaaf LJ, et al. Among authors: miller ll. Clin Cancer Res. 2006 Jun 15;12(12):3782-91. doi: 10.1158/1078-0432.CCR-05-2152. Clin Cancer Res. 2006. PMID: 16778106 Clinical Trial.
414 results